Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1322 - Surgical resection of primary tumor is prolonged survival in metastatic pancreatic neuroendocrine carcinoma

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Tingting Feng

Citation

Annals of Oncology (2018) 29 (suppl_8): viii467-viii478. 10.1093/annonc/mdy293

Authors

T. Feng

Author affiliations

  • Abdominal Medical Oncology, Zhejiang Cancer Hospital, 310022 - Hangzhou/CN
More

Resources

Abstract 1322

Background

Most of pancreatic neuroendocrine carcinoma (PanNEC) present with distant metastases. Removal of the primary tumor is not recommended for metastatic PanNEC patients considering the limited survival benefit compared to well differentiated grade patients. However, published data to support these recommendations regarding PanNEC are scarce. The aim of this study was to assess whether resection of the primary tumor in patients with stage IV PanNEC has an impact on survival.

Methods

Patients with stage IV PanNEC registered in the Surveillance, Epidemiology, and End Results database between 1973 and 2014 were identified. The specific criteria are as follows:1 The histologic subtypes and their ICD-O-3: large cell neuroendocrine carcinoma(8013), small cell carcinoma(8041) and neuroendocrine carcinoma (8246); 2 histologic differentiation grade: poorly differentiated and undifferentiated; 3 Diagnostic confirmation is “Positive histology“; 4 the age ≥ 18 years and ≤ 85 years; 5 “SEER historic stage” variable is“distant”or AJCC stage IV;6.Survival months flag is ”Complete dates are available and there are more than 0 days of survival”. Overall (OS) and cancer-specific survival (CSS) of patients who did and did not undergo resection of their primary tumor were compared by means of risk-adjusted Cox proportional hazard regression analysis and propensity score matched analysis.

Results

We identified 461 patients with metastatic PanNEC and survival data. 15.8% (73/461) of patients had surgical removal of their primary tumor. Median survival of patients undergoing primary tumor resection was 28 (95% CI: 4.751-51.249) versus 6 (95% CI: 4.672-7.328) months for those without resection (p < 0.0001). Patients underwent primary tumor resection showed a significant benefit in both OS (HR of death=0.296, 95%CI 0.206–0.424, p < 0.001) and CSS (HR of death=0.329, 95 % CI 0.219–0.493, p < 0.001) in unadjusted multivariate Cox regression analysis; the benefit persisted after propensity score adjustment.

Conclusions

The recent recommendations judging resection of the primary as inadvisable and the accompanying trend towards fewer palliative resections of the primary tumor in IV stage PanNEC have to be contested.

Clinical trial identification

Legal entity responsible for the study

Fengtingting.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings